ENDO 2026

Summaries from ENDO 2026, held from June 13 – 16, 2026.

EHR-based AI model may enable expanded screening for primary aldosteronism, researchers report

Presenter: Frank G. Lee, MD, Mayo Clinic Rochester, Rochester, MN

AI-based approach to screening primary aldosteronism. Presented June 13, 2026.

Once-weekly therapy may address unmet needs for patients with hypoparathyroidism, phase 2 study suggests

Presenter: Mishaela R. Rubin, MD, Assistant Professor of Clinical Medicine, Columbia University Irving Medical Center, New York, NY

Efficacy and safety of once-weekly canvuparatide in patients with hypoparathyroidism: results from AVAIL, a phase 2 randomized clinical trial. Presented June 13, 2026.

Study highlights potential role of restoring cortisol circadian rhythm in Cushing syndrome recovery

Presenter: Angeliki Theodorou, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Impact of cortisol circadian rhythm on psychological well-being and functional outcomes in treated endogenous Cushing syndrome: a cross-sectional study. Presented June 14, 2026.

Novel continuous glucose monitoring-derived index may help identify hypoglycemia fragility in type 1 diabetes

Presenter: Satanay Mahmoud, MD, Tucson Medical Center, Tucson AZ

Why hypoglycemia occurs despite stable glucose patterns: a novel CGM-derived measure of hypoglycemia fragility in patients with type 1 diabetes mellitus. Presented June 14, 2026.

Real-world data highlight cardiometabolic consequences of chronic glucocorticoid exposure and poor androgen control in classic congenital adrenal hyperplasia

Presenter: Oksana Lekarev, DO, Weill Cornell Medicine, New York, NY

Long-term risk of cardiometabolic comorbidities associated with glucocorticoid exposure and androgen control in classic congenital adrenal hyperplasia: a Cox proportional hazards analysis from the CAHtalog registry. Presented June 14, 2026.

Orphan drug improves blood calcium levels and reduces reliance on conventional hypoparathyroidism therapy in adults, PaTHway analysis shows

Presenter: Bart L. Clarke, MD, Mayo Clinic, Rochester, MN

Palopegteriparatide treatment in adults with hypoparathyroidism: final results of the phase 3 PaTHway trial. Presented June 13, 2026.

ACTH-independent hypercortisolism is most common in patients with diabetes and obesity, secondary analysis shows

Presenter: Andrew J. Newman, MD, Brigham and Women's Hospital/Mass General Brigham, Harvard Medical School, Boston, MA

ACTH-independent hypercortisolism across the cardiometabolic spectrum. Presented June 13, 2026.

Crinecerfont shows durable improvements in classic congenital adrenal hyperplasia and reduces glucocorticoid doses in phase-3 CAHtalyst trial

Presenter: Oksana Hamidi, DO, MSCS, UT Southwestern Medical Center, Dallas, TX

Crinecerfont improves weight-related outcomes and insulin resistance in adults with classic congenital adrenal hyperplasia: 2-year results from the CAHtalyst adult study. Presented June 14, 2026.

Ersodetug shows potential clinical activity in congenital hyperinsulinism, Phase 3 sunRIZE trial suggests

Presenter: Huseyin Demirbilek, MD, Professor, Hacettepe University Faculty of Medicine, Department of Pediatric Endocrinology, Sihhiye/Ankara, Türkiye

Ersodetug (RZ358) in congenital hyperinsulinism: top-line results from a global, multicenter, randomized, double-blind, placebo-controlled phase 3 study (sunRIZE). Presented June 13, 2026.